Navigation Links
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Date:9/24/2008

company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
4. InterMune to Present at BMO Healthcare Conference
5. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
6. InterMune to Present at Jefferies Healthcare Conference
7. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
8. InterMune to Present at Citigroup Healthcare Conference
9. InterMune to Present at Bank of America Health Care Conference
10. InterMune to Present at Deutsche Bank Health Care Conference
11. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.538 04/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , , ... , , , , , , , , ... Azotobacter vinelandii, , , ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 , ... , , , ... , Cell type , Bacteria, gram negative, ...
Cached Biology Technology:Bifidobacterium animalis 2Azotobacter vinelandii 2Actinomyces viscosus 2
(Date:4/21/2014)... mountains across the western United States are dying, thanks to ... inner bark. , Some species of the beetles, such ... Others live in dead, weakened or dying hosts. , In ... of more than 3.4 million acres of pine trees. , ... flow and water quality? Plenty, according to new research findings ...
(Date:4/21/2014)... are on the decline in the Galpagos. , A new ... indicates numbers of the iconic birds, known for their ... attract mates, have fallen more than 50 percent in less ... is probably due to an unexplained disappearance of sardines from ... at Wake Forest University and the study,s principal investigator. This ...
(Date:4/21/2014)... from Pittsburgh University, find how lipid mediators are ... Chemistry. Lipid mediators are molecules playing an important ... some of them has earned a Nobel prize ... power plants", the organelles where oxidation of various ... a molecule universally used for storage and transportation ...
Breaking Biology News(10 mins):Earth Week: Bark beetles change Rocky Mountain stream flows, affect water quality 2Earth Week: Bark beetles change Rocky Mountain stream flows, affect water quality 3Lack of breeding threatens blue-footed boobies' survival 2Lack of breeding threatens blue-footed boobies' survival 3The anti-inflammatory factory 2The anti-inflammatory factory 3
... of the Neanderthal genome persists in modern human populations. ... 665 people from Europe and East Asia shows that more ... DNA of this contemporary group, whose genetic information is part ... that someone of non-African descent may have inherited approximately 1 ...
... thousand years ago, Homo sapiens migrating out ... diverged from modern humans hundreds of thousands of years ... Neanderthals mingled, and over time, produced children with genes ... collision between two distinct populations remain alive in the ...
... a single gene in honey bees separates the queens from ... University and Wayne State University unraveled the gene,s inner workings ... Biology Letters . The gene, which is responsible for leg ... of bees, ability to carry pollen. "This gene is ...
Cached Biology News:Neanderthal lineages excavated from modern human genomes 2Neanderthal lineages excavated from modern human genomes 3When populations collide 2When populations collide 3When populations collide 4Single gene separates queen from workers 2